Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:COGT NASDAQ:SRRK NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$73.73+2.5%$64.55$23.65▼$75.50$6.35B0.311.19 million shs1.09 million shsCOGTCogent Biosciences$38.74+1.7%$34.54$7.07▼$43.73$6.51B0.343.00 million shs3.22 million shsSRRKScholar Rock$54.96+0.4%$47.94$27.07▼$56.54$6.56B0.691.68 million shs2.10 million shsZYMEZymeworks$24.10-0.2%$25.05$11.51▼$29.75$1.76B1.15695,985 shs1.06 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology+2.46%+11.29%+18.37%+8.94%+184.12%COGTCogent Biosciences+1.64%+8.09%+10.81%+0.78%+445.63%SRRKScholar Rock+0.37%+11.73%+11.48%+11.80%+53.48%ZYMEZymeworks-0.21%+3.61%-4.10%-3.75%+2,409,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$73.73+2.5%$64.55$23.65▼$75.50$6.35B0.311.19 million shs1.09 million shsCOGTCogent Biosciences$38.74+1.7%$34.54$7.07▼$43.73$6.51B0.343.00 million shs3.22 million shsSRRKScholar Rock$54.96+0.4%$47.94$27.07▼$56.54$6.56B0.691.68 million shs2.10 million shsZYMEZymeworks$24.10-0.2%$25.05$11.51▼$29.75$1.76B1.15695,985 shs1.06 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology+2.46%+11.29%+18.37%+8.94%+184.12%COGTCogent Biosciences+1.64%+8.09%+10.81%+0.78%+445.63%SRRKScholar Rock+0.37%+11.73%+11.48%+11.80%+53.48%ZYMEZymeworks-0.21%+3.61%-4.10%-3.75%+2,409,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.71Moderate Buy$81.7310.85% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7312.87% UpsideSRRKScholar Rock 3.12Buy$56.001.89% UpsideZYMEZymeworks 2.82Moderate Buy$36.6752.14% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, COGT, SRRK, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/9/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.006/3/2026ZYMEZymeworks HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/19/2026CGONCG Oncology Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026CGONCG Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.005/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/11/2026CGONCG Oncology JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$91.00 ➝ $96.005/11/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$79.00 ➝ $81.005/11/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $77.005/11/2026CGONCG Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $80.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$5.07M1,282.42N/AN/A$9.33 per share7.90COGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ASRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/AZYMEZymeworks$105.96M16.61N/AN/A$3.59 per share6.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/AN/AN/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ZYME, COGT, SRRK, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A31.3031.25COGTCogent Biosciences0.4115.1415.14SRRKScholar Rock0.718.648.64ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%COGTCogent BiosciencesN/ASRRKScholar Rock91.08%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%COGTCogent Biosciences6.59%SRRKScholar Rock13.30%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.20 million83.97 millionOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AZYME, COGT, SRRK, and CGON HeadlinesRecent News About These CompaniesTheravance, after clinical setbacks, agrees to $929M buyoutJune 29 at 6:16 PM | finance.yahoo.comZymeworks offers US$929-million for COPD drug maker TheravanceJune 29 at 6:16 PM | theglobeandmail.comZymeworks to buy Theravance for $929 million in push to expand beyond cancerJune 29 at 6:16 PM | msn.comZymeworks Inc. (ZYME) M&A Call TranscriptJune 29 at 4:00 PM | seekingalpha.comPharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance BiopharmaJune 29 at 11:51 AM | pharmexec.comPWhy This Biotech Stock Is Falling After a $929 Million Buyout LifelineJune 29 at 11:51 AM | msn.comZymeworks cuts deal to buy Theravance for $929m in cashJune 29 at 11:51 AM | pharmaphorum.comPZymeworks to Buy Theravance Biopharma for About $929 MillionJune 29 at 11:51 AM | marketwatch.comZymeworks acquires struggling Theravance for $929MJune 29 at 11:51 AM | fiercepharma.comFZymeworks expands beyond cancer with $929 million Theravance acquisitionJune 29 at 11:51 AM | msn.comZymeworks Inc.: Zymeworks to Acquire Theravance Biopharma, Inc.June 29 at 6:50 AM | finanznachrichten.deZymeworks Strikes $929 Million Deal for TheravanceJune 29 at 6:50 AM | bloomberg.comZymeworks strikes $929 million deal for Theravance BiopharmaJune 29 at 6:13 AM | reuters.comZymeworks to Acquire Theravance Biopharma, Inc.June 29 at 6:00 AM | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Zymeworks (ZYME)June 24, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)June 19, 2026 | theglobeandmail.comGandeeva, Zymeworks Using Cryo-EM to Enhance Antibody Drug DiscoveryJune 18, 2026 | contractpharma.comCGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug DiscoveryJune 18, 2026 | prnewswire.comZymeworks Inc. Reports Promising Phase 1 Results for ZW191 in Platinum-Resistant Ovarian Cancer PatientsJune 14, 2026 | quiverquant.comQZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026June 14, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, COGT, SRRK, and CGON Company DescriptionsCG Oncology NASDAQ:CGON$73.73 +1.77 (+2.46%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$75.05 +1.32 (+1.79%) As of 05:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Cogent Biosciences NASDAQ:COGT$38.74 +0.64 (+1.68%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$38.74 +0.00 (+0.01%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Scholar Rock NASDAQ:SRRK$54.96 +0.20 (+0.37%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$54.98 +0.02 (+0.03%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Zymeworks NASDAQ:ZYME$24.10 -0.05 (-0.21%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$24.22 +0.12 (+0.51%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
